Home › Triple-Negative Breast Cancer › Nebraska
Triple-Negative Breast Cancer clinical trials in Nebraska
6 studies for Triple-Negative Breast Cancer are looking for participants at sites in Nebraska.
Cities in Nebraska
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
- XCancer, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- University of Nebraska Medical Center, Omaha
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06799065A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Cancer Partners of Nebraska ( Site 0068), Lincoln
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Oncology Hematology West - Methodist, Omaha
- Nebraska Methodist Hospital (change from Chi Health Bergan Mercy), Omaha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05633654Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403CtDNA Based MRD Testing for NAC Monitoring in TNBC
- Nebraska Methodist, Omaha
RecruitingObservational study
Ages 18 and older · Women · Updated Jan 7, 2025 · NCT06230185From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.